518 related articles for article (PubMed ID: 30392780)
21. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
23. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
24. A CT-based radiomics nomogram for predicting early recurrence in patients with high-grade serous ovarian cancer.
Chen HZ; Wang XR; Zhao FM; Chen XJ; Li XS; Ning G; Guo YK
Eur J Radiol; 2021 Dec; 145():110018. PubMed ID: 34773830
[TBL] [Abstract][Full Text] [Related]
25. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
Kim SI; Hwangbo S; Dan K; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
Mol Cell Proteomics; 2023 Mar; 22(3):100502. PubMed ID: 36669591
[TBL] [Abstract][Full Text] [Related]
26. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
[TBL] [Abstract][Full Text] [Related]
27. A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study.
Wei W; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wang S; Wang M; Guo Y; Tian J
Front Oncol; 2019; 9():255. PubMed ID: 31024855
[No Abstract] [Full Text] [Related]
28. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
29. Deep learning radiomics analysis based on computed tomography for survival prediction in gastric neuroendocrine neoplasm: a multicenter study.
Yang Z; Han Y; Li F; Zhang A; Cheng M; Gao J
Quant Imaging Med Surg; 2023 Dec; 13(12):8190-8203. PubMed ID: 38106311
[TBL] [Abstract][Full Text] [Related]
30. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
31. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
32. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
33. Whole solid tumor volume histogram parameters for predicting the recurrence in patients with epithelial ovarian carcinoma: a feasibility study on quantitative DCE-MRI.
Li HM; Tang W; Feng F; Zhao SH; Gu WY; Zhang GF; Qiang JW
Acta Radiol; 2020 Sep; 61(9):1266-1276. PubMed ID: 31955611
[TBL] [Abstract][Full Text] [Related]
34. High
Li XF; Zhang HB; Huo Y
J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
[TBL] [Abstract][Full Text] [Related]
35. Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome.
Josahkian JA; Saggioro FP; Vidotto T; Ventura HT; Candido Dos Reis FJ; de Sousa CB; Tiezzi DG; de Andrade JM; Koti M; Squire JA
Int J Gynecol Cancer; 2018 Mar; 28(3):459-465. PubMed ID: 29303938
[TBL] [Abstract][Full Text] [Related]
36. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
37. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
Nougaret S; Lakhman Y; Gönen M; Goldman DA; Miccò M; D'Anastasi M; Johnson SA; Juluru K; Arnold AG; Sosa RE; Soslow RA; Vargas HA; Hricak H; Kauff ND; Sala E
Radiology; 2017 Nov; 285(2):472-481. PubMed ID: 28628421
[TBL] [Abstract][Full Text] [Related]
38. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
39. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H; Chen L; Zhang M; Luo Y; Ma X
Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
[TBL] [Abstract][Full Text] [Related]
40. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
